Sign Out
Tablet and oral solution: Ferriprox is indicated for the treatment of iron overload in patients 1 year of age and older with thalassaemia major.
Approval is based on a reduction in serum ferritin levels. There are no controlled trials demonstrating a direct treatment benefit, such as improvement in disease-related symptoms, functioning, or increased survival (see Pharmacology: Toxicology: Oral Solution: Clinical Studies under Actions).
Limitation of Use: Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with other chronic anemias.
